---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-020257"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:10:14.727151+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing

## Summary
- FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.
- Preclinical combo data: FHD-909 synergistic with pembrolizumab and KRAS inhibitors, supporting clinical exploration.
- Selective CBP degrader synergistic with paclitaxel and abemaciclib in ER+ breast cancer models.
- Selective EP300 degrader shows preclinical activity in DLBCL and multiple myeloma; no thrombocytopenia.
- ARID1B degrader program update expected in 2H 2025.

## SEC filing metadata
- accession: 0001628280-25-020257
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025020257/0001628280-25-020257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025020257/fhtx-20250428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-020257
- JSON: https://secwatch.observer/filing/0001628280-25-020257.json
- Plain text: https://secwatch.observer/filing/0001628280-25-020257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.